SCM
NVCR icon

Sterling Capital Management’s NovoCure NVCR Stock Holding History

Sterling Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.19K Sell
660
-15
-2% -$187 ﹤0.01% 2556
2025
Q4 		$8.73K Buy
675
+429
+174% +$5.51K ﹤0.01% 2675
2025
Q3 		$3.18K Hold
246
– – ﹤0.01% 2900
2025
Q2 		$4.38K Buy
246
+135
+122% +$2.35K ﹤0.01% 2581
2025
Q1 		$1.98K Buy
111
+4
+4% +$91 ﹤0.01% 2613
2024
Q4 		$3.19K Sell
107
-3
-3% -$63 ﹤0.01% 2629
2024
Q3 		$1.72K Buy
+110
New +$2K ﹤0.01% 2252

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Sterling Capital Management's NVCR Position: Q1 2026 in Review

Sterling Capital Management reduced its NovoCure (NVCR) stake by 2.2% in Q1 2026, selling an estimated $187 and leaving 660 shares worth $7.19K. The position accounts for ﹤0.01% of the portfolio, ranked #2556.

Sterling Capital Management first reported a position in NVCR in Q3 2024 and has held it in 7 quarters since. The position peaked at $8.73K in Q4 2025. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Sterling Capital Management held 660 shares of NovoCure worth $7.19K as of Q1 2026.
  • Sterling Capital Management sold 15 NovoCure shares in Q1 2026, an estimated $187.
  • NovoCure made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #2556 holding.
  • Sterling Capital Management first reported a position in NovoCure in Q3 2024 and has held it in 7 quarters since.
  • Sterling Capital Management's NovoCure position peaked at $8.73K in Q4 2025.
  • 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.